I型干扰素与JAK抑制剂引起的基因变化:幼年皮肌炎驱动因素的线索
研究在健康儿童供体来源的三维骨骼肌单元中,观察I型干扰素(IFNα或IFNβ)及JAK抑制剂托法替布或巴瑞替尼对基因表达的影响,发现IFNβ较IFNα引起更强的促炎基因上调并降低收缩蛋白基因表达和收缩力,巴瑞替尼较托法替布更多改变基因谱并部分逆转IFN I诱导的变化。
要点
- IFNβ较IFNα引起更显著的干扰素反应和促炎基因上调。
- IFN I下调氧化磷酸化、脂肪酸代谢和肌生成基因。
- 巴瑞替尼较托法替布更多改变基因谱并部分逆转IFNβ诱导的变化。
核心结论
- IFNβ较IFNα引起更强的促炎基因上调,与收缩蛋白基因表达下降和收缩力降低相关。
- JAK抑制剂中巴瑞替尼较托法替布更多部分逆转IFN I诱导的基因变化。
- 健康生物工程骨骼肌中IFN I暴露导致干扰素诱导基因表达、炎症通路富集和肌生成基因下调,与幼年皮肌炎中所见一致。
研究设计与样本
- 使用三名健康儿童供体的成肌细胞构建三维骨骼肌单元(myobundles)。
- myobundles接受IFNα或IFNβ处理,部分IFNβ暴露的myobundles接受托法替布或巴瑞替尼处理。
- 对所有myobundles进行RNA测序分析,共分析76个myobundles。
主要发现
- 主成分分析显示IFNα和IFNβ暴露的myobundles基因表达呈剂量依赖性供体特异性聚类。
- 两种细胞因子均上调干扰素反应和促炎基因,但IFNβ导致更显著的上调。
- 关键下调通路涉及氧化磷酸化、脂肪酸代谢和肌生成基因。
- 加入托法替布或巴瑞替尼减轻IFNβ诱导的基因表达,部分逆转上调的炎症通路和下调的肌生成通路。
- 巴瑞替尼较托法替布更多改变基因谱。
关键数值与推荐
- 共分析76个myobundles。
- IFNβ较IFNα引起更显著的促炎基因上调。
- 巴瑞替尼较托法替布更多改变基因谱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To better understand the pathogenesis of juvenile dermatomyositis (JDM), we examined the effect of the cytokines type I interferons (IFN I) and JAK inhibitor drugs (JAKi) on gene expression in bioengineered pediatric skeletal muscle. METHODS: Myoblasts from three healthy pediatric donors were used to create three-dimensional skeletal muscle units termed myobundles. Myobundles were treated with IFN I, either IFNα or IFNβ. A subset of IFNβ-exposed myobundles was treated with JAKi tofacitinib or baricitinib. RNA sequencing analysis was performed on all myobundles. RESULTS: Seventy-six myobundles were analysed. Principal component analysis showed donor-specific clusters of gene expression across IFNα and IFNβ-exposed myobundles in a dose-dependent manner. Both cytokines upregulated interferon response and proinflammatory genes; however, IFNβ led to more significant upregulation. Key downregulated pathways involved oxidative phosphorylation, fatty acid metabolism and myogenesis genes. Addition of tofacitinib or baricitinib moderated the gene expression induced by IFNβ, with partial reversal of upregulated inflammatory and downregulated myogenesis pathways. Baricitinib altered genetic profiles more than tofacitinib. CONCLUSION: IFNβ leads to more pro-inflammatory gene upregulation than IFNα, correlating to greater decrease in contractile protein gene expression and reduced contractile force. JAK inhibitors, baricitinib more so than tofacitinib, partially reverse IFN I-induced genetic changes. Increased IFN I exposure in healthy bioengineered skeletal muscle leads to IFN-inducible gene expression, inflammatory pathway enrichment, and myogenesis gene downregulation, consistent with what is observed in JDM.
引用
- Covert LT, Prinz JA, Swain-Lenz D, et al. Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis. Rheumatology (Oxford). 2024. PMID: 38317053. doi:10.1093/rheumatology/keae082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。